Friday November 27 2009 | Biotechnology feed | All feeds
|
|
|
GlaxoSmithKlinehttp://us.gsk.com Smithkline Beecham Corporation, Philadelphia PA, United States of America.
GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, USWednesday 1st of April 2009 9:00BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:
 Browse other news from this organisation: GlaxoSmithKline Related Web-Links(If any, Generated Automatically)
Source PR Newswire  |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
